Skip to main content

Table 1 Baseline, end-of-treatment, and percent change values for lipoprotein particle sizes and concentrationsa,b

From: Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial

  Statin + OO Statin + OM3-CA Statin + OM3-CA
  4 g/d 2 g/dc 4 g/d
Variable (n = 211) (n = 209) (n = 207)
Lipoprotein particle sizes
VLDL (nm)
  Baseline 55.0 (5.7) 55.4 (5.6) 55.2 (5.9)
  End-of-treatment 54.7 (5.9) 52.2 (5.4) 50.8 (5.8)
  %Δ LSM-BT (95 % CI) −0.6 (−1.7, 0.4) −5.6 (−6.6, −4.6)*** −8.0 (−9.0, −7.0)***
LDL (nm)    
  Baseline 19.9 (0.4) 19.9 (0.3) 19.9 (0.4)
  End-of-treatmentd 19.9 (0.4) 20.0 (0.4) 20.1 (0.4)
  %Δ LSM-BT (95 % CI) −0.1 (−0.2, 0.1) 0.3 (0.1, 0.5)** 0.6 (0.4, 0.8)***
HDL (nm)    
  Baseline 8.5 (0.3) 8.5 (0.3) 8.5 (0.3)
  End-of-treatment 8.5 (0.3) 8.4 (0.3) 8.4 (0.4)
  %Δ LSM-BT (95 % CI) −0.2 (−0.5, 0.1) −0.6 (−0.9, −0.2)* −0.5 (−0.9, −0.2)*
Lipoprotein particle concentrations
Total VLDL/chylomicron remnant (nmol/L)
  Baseline 129 (47.0) 128 (43.0) 130 (48.2)
  End-of-treatment 123 (53.4) 119 (47.0) 114 (54.4)
  %Δ LSM-BT (95 % CI) −6.9 (−11.1, −2.5) −8.5 (−12.6, −4.1) −16.0 (−19.8, −12.0)**
 Large VLDL/chylomicron remnant (nmol/L)
  Baseline 13.2 (7.2) 14.0 (7.4) 13.9 (8.3)
  End-of-treatment 12.7 (7.9) 9.6 (7.3) 7.5 (6.8)
  %Δ LSM-BT (95 % CI) −10.1 (−17.5, −2.0) −36.8 (−42.0, −31.1)*** −55.8 (−59.5, −51.8)***
 Medium VLDL (nmol/L)
  Baseline 72.1 (30.9) 69.7 (32.2) 72.0 (37.4)
  End-of-treatment 68.4 (35.5) 62.9 (33.2) 60.0 (36.3)
  %Δ LSM-BT (95 % CI) −9.7 (−15.5, −3.5) −12.6 (−18.2, −6.5) −22.8 (−27.8, −17.4)*
 Small VLDL (nmol/L)
  Baseline 43.5 (31.1) 44.3 (25.5) 44.2 (29.5)
  End-of-treatment 42.4 (30.4) 46.8 (28.3) 46.8 (30.4)
  %Δ LSM-BT (95 % CI) −1.1 (−10.1, 8.7) 4.7 (−4.8, 15.3) 8.6 (−1.4, 19.6)
Total LDL (nmol/L)
  Baseline 1286 (360) 1309 (357) 1323 (342)
  End-of-treatment 1317 (374) 1359 (391) 1359 (378)
  %Δ LSM-BT (95 % CI) 2.0 (−0.6, 4.5) 3.3 (0.8, 6.0) 2.4 (−0.2, 5.0)
 IDL (nmol/L)
  Baseline 74.9 (77.2) 79.0 (78.5) 75.5 (76.6)
  End-of-treatment 75.6 (92.0) 72.9 (73.8) 70.7 (78.9)
  %Δ LSM-BT (95 % CI) −13.5 (−25.2, 0.2) −6.9 (−19.7, 7.8) −15.7 (−27.3, −2.3)
 Large LDL (nmol/L)
  Baseline 661 (576) 660 (569) 656 (592)
  End-of-treatment 389 (408) 439 (440) 445 (407)
  %Δ LSM-BT (95 % CI) −49.8 (−58.5, −39.3) −40.1 (−50.6, −27.4)*** −21.6 (−35.4, −4.7)***
 Small LDL (nmol/L)
  Baseline 1004 (310) 1014 (313) 1033 (296)
  End-of-treatment 1024 (325) 1023 (331) 1008 (334)
  %Δ LSM-BT (95 % CI) 1.0 (−2.7, 4.7) 0.3 (−3.3, 4.1) −4.2 (−7.7, −0.7)*
Total HDL (mmol/L)
  Baseline 32.8 (5.8) 32.7 (6.2) 32.6 (6.8)
  End-of-treatment 33.0 (6.1) 32.3 (6.1) 31.6 (6.7)
  %Δ LSM-BT (95 % CI) 0.6 (−0.7, 1.9) −1.5 (−2.8, −0.2)* −3.2 (−4.5, −1.9)***
 Large HDL (mmol/L)
  Baseline 2.6 (1.9) 2.4 (1.8) 2.4 (1.9)
  End-of-treatment 2.6 (1.8) 2.2 (2.0) 2.2 (2.3)
  %Δ LSM-BT (95 % CI) −6.9 (−20.9, 9.5) −39.0 (−48.2, −28.1)*** −29.0 (−39.8, −16.3)***
 Medium HDL (mmol/L)
  Baseline 6.0 (3.2) 6.1 (3.4) 6.5 (5.1)
  End-of-treatment 5.9 (3.4) 6.3 (3.3) 6.7 (3.5)
  %Δ LSM-BT (95 % CI) −6.6 (−12.2, −0.7) 3.9 (−2.4, 10.5)* 11.3 (4.6, 18.4)***
 Small HDL (mmol/L)
  Baseline 24.1 (4.7) 24.2 (4.5) 23.7 (4.9)
  End-of-treatment 24.5 (5.0) 23.7 (4.8) 22.7 (4.6)
  %Δ LSM-BT (95 % CI) 1.7 (−1.0, 4.4) −1.9 (−4.5, 0.7)** −3.6 (−6.1, −1.0)***
  1. Abbreviations: %∆ percent change, CI confidence interval, HDL high-density lipoprotein, IDL = intermediate-density lipoprotein, LDL low-density lipoprotein, LSM-BT least-squares means–back transformed, OM3-CA omega-3 carboxylic acids, OO Olive oil, VLDL very low-density lipoprotein
  2. aMeans (standard deviation) are presented for baseline and end-of-treatment values
  3. bSuperscript letters represent p-values for each OM3-CA dosage vs. OO: * p < 0.05, ** p < 0.01, and *** p < 0.001
  4. cPatients in the OM3-CA 2 g/d treatment arm also received OO capsules at a dosage of 2 g/d
  5. dNumber of patients with data in the OM3-CA 2 g/d treatment group = 208